Fibronectin-α4β1 integrin interactions regulate metalloproteinase-9 expression in steatotic liver ischemia and reperfusion injury

American Journal of Pathology

Volumn 170, Issue 2, 2007, Pages 567-577

  Moore, Carolina ^a   Shen, Xiu Da ^a   Gao, Feng ^a   Busuttil, Ronald W ^a   Coito, Ana J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; FIBRONECTIN; GELATINASE A; GELATINASE B; INTEGRIN; INTERLEUKIN 1BETA; MATRIX PROTEIN; METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA; VERY LATE ACTIVATION ANTIGEN 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME REGULATION; FATTY LIVER; HISTOLOGY; IMMUNOHISTOCHEMISTRY; LEUKOCYTE; LIVER ISCHEMIA; LIVER TRANSPLANTATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; RAT; REPERFUSION INJURY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; T LYMPHOCYTE; WESTERN BLOTTING; ZYMOGRAPHY; ANIMAL; BIOSYNTHESIS; COLD ISCHEMIA; ENZYMOLOGY; GENE EXPRESSION REGULATION; ISOGRAFT; LIVER; MACROPHAGE; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT; UPREGULATION; ZUCKER RAT;

ANIMALS; COLD ISCHEMIA; FATTY LIVER; GENE EXPRESSION REGULATION, ENZYMOLOGIC; INTEGRIN ALPHA4BETA1; INTERLEUKIN-1BETA; LIVER; LIVER TRANSPLANTATION; MACROPHAGES; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; RATS; RATS, SPRAGUE-DAWLEY; RATS, ZUCKER; REPERFUSION INJURY; T-LYMPHOCYTES; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRANSPLANTATION, ISOGENEIC; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 33947545387     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2007.060456     Document Type: Article

References (59)

1. Alexander JW, Vaughn WK: The use of "marginal" donors for organ transplantation: the influence of donor age on outcome. Transplantation 1991, 51:135-141
2. Lehmann TG, Wheeler MD, Schwabe RF, Connor HD, Schoonhoven R, Bunzendahl H, Brenner DA, Jude SR, Zhong Z, Thurman RG: Gene delivery of Cu/Zn-superoxide dismutase improves graft function after transplantation of fatty livers in the rat. Hepatology 2000, 32:1255-1264
3. Koneru B, Dikdan G: Hepatic steatosis and liver transplantation current clinical and experimental perspectives. Transplantation 2002, 73:325-330
4. Strasberg SM, Howard TK, Molmenti EP, and Hertl M: Selecting the donor liver: risk factors for poor function after orthotopic liver transplantation. Hepatology 1994, 20:829-838
5. Coito AJ, de Sousa M, Kupiec-Weglinski JW: Fibronectin in immune responses in organ transplant recipients. Dev Immunol 2000, 7:239-248
6. Shimizu Y, van Seventer GA, Horgan KJ, Shaw S: Costimulation of proliferative responses of resting CD4+ T cells by the interaction of VLA-4 and VLA-5 with fibronectin or VLA-6 with laminin. J Immunol 1990, 145:59-67
7. Hauzenberger D, Klominek J, Sundqvist KG: Functional specialization of fibronectin-binding β1-integrins in T lymphocyte migration. J Immunol 1994, 153:960-971
8. Coito AJ, Binder J, Brown LF, de Sousa M, Van De WL, Kupiec-Weglinski JW: Anti-TNF-α treatment down-regulates the expression of fibronectin and decreases cellular infiltration of cardiac allografts in rats. J Immunol 1995, 154:2949-2958
9. Xia P, Culp LA: Adhesion activity in fibronectin's alternatively spliced domain EDa (EIIIA): complementarity to plasma fibronectin functions. Exp Cell Res 1995, 217:517-527
10. Manabe R, Oh-e N, Sekiguchi K: Alternatively spliced EDA segment regulates fibronectin-dependent cell cycle progression and mitogenic signal transduction. J Biol Chem 1999, 274:5919-5924
11. Amersi F, Shen XD, Moore C, Melinek J, Busuttil RW, Kupiec Weglinski JW, Coito AJ: Fibronectin-α4β1 integrin-mediated blockade protects genetically fat Zucker rat livers from ischemia/reperfusion injury. Am J Pathol 2003, 162:1229-1239
12. Bianchi E, Bender JR, Blasi F, Pardi R: Through and beyond the wall: late steps in leukocyte transendothelial migration. Immunol Today 1997, 18:586-591
13. Lee MH, Murphy G: Matrix metalloproteinases at a glance. J Cell Sci 2004, 117:4015-4016
14. Yoshizaki T, Sato H, Furukawa M, Pagano JS: The expression of matrix metalloproteinase 9 is enhanced by Epstein-Barr virus latent membrane protein 1. Proc Natl Acad Sci USA 1998, 95:3621-3626
15. Nagase H, Woessner JF Jr.: Matrix metalloproteinases. J Biol Chem 1999, 274:21491-21494
16. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D: Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000, 2:737-744
17. Yu Q, Stamenkovic I: Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. Genes Dev 2000, 14:163-176
18. Giannelli G, Erriquez R, Iannone F, Marinosci F, Lapadula G, Antonaci S: MMP-2, MMP-9, TIMP-1 and TIMP-2 levels in patients with rheumatoid arthritis and psoriatic arthritis. Clin Exp Rheumatol 2004, 22:335-338
19. Dong Z, Bonfil RD, Chinni S, Deng X, Trindade Filho JC, Bernardo M, Vaishampayan U, Che M, Sloane BF, Sheng S, Fridman R, Cher ML: Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue. Am J Pathol 2005, 166:1173-1186
20. Kamada N, Calne RY: Orthotopic liver transplantation in the rat: technique using cuff for portal vein anastomosis and biliary drainage. Transplantation 1979, 28:47-50
21. Kamada N, Calne RY: A surgical experience with five hundred thirty liver transplants in the rat. Surgery 1983, 93:64-69
22. Coito AJ, Onodera K, Kato H, Busuttil RW, Kupiec-Weglinski JW: Fibronectin-mononuclear cell interactions regulate type 1 helper T cell cytokine network in tolerant transplant recipients. Am J Pathol 2000, 157:1207-1218
23. Elices MJ, Osborn L, Takada Y, Crouse C, Luhowskyj S, Hemler ME, Lobb RR: VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 1990, 60:577-584
24. Elices MJ, Tsai V, Strahl D, Goel AS, Tollefson V, Arrhenius T, Wayner EA, Gaeta FC, Fikes JD, Firestein GS: Expression and functional significance of alternatively spliced CS1 fibronectin in rheumatoid arthritis microvasculature. J Clin Invest 1994, 93:405-416
25. Makarem R, Newham P, Askari JA, Green LJ, Clements J, Edwards M, Humphries MJ, Mould AP: Competitive binding of vascular cell adhesion molecule-1 and the HepII/IIICS domain of fibronectin to the integrin α4β1. J Biol Chem 1994, 269:4005-4011
26. Wahl SM, Allen JB, Hines KL, Imamichi T, Wahl AM, Furcht LT, McCarthy JB: Synthetic fibronectin peptides suppress arthritis in rats by interrupting leukocyte adhesion and recruitment. J Clin Invest 1994, 94:655-662
27. Suzuki S, Toledo-Pereyra LH, Rodriguez FJ, Cejalvo D: Neutrophil infiltration as an important factor in liver ischemia and reperfusion injury: modulating effects of FK506 and cyclosporine. Transplantation 1993, 55:1265-1272
28. Coito AJ, Brown LF, Peters JH, Kupiec-Weglinski JW, Van De WL: Expression of fibronectin splicing variants in organ transplantation: a differential pattern between rat cardiac allografts and isografts. Am J Pathol 1997, 150:1757-1772
29. Coito AJ, Shaw GD, Li J, Ke B, Ma J, Busuttil RW, Kupiec-Weglinski JW: Selectin-mediated interactions regulate cytokine networks and macrophage heme oxygenase-1 induction in cardiac allograft recipients. Lab Invest 2002, 82:61-70
30. Basbaum CB, Werb Z: Focalized proteolysis: spatial and temporal regulation of extracellular matrix degradation at the cell surface. Curr Opin Cell Biol 1996, 8:731-738
31. Owen CA, Campbell EJ: The cell biology of leukocyte-mediated proteolysis. J Leukoc Biol 1999, 65:137-150
32. Visse R, Nagase H: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003, 92:827-839
33. Bode W, Fernandez-Catalan C, Grams F, Gomis-Ruth FX, Nagase H, Tschesche H, Maskos K: Insights into MMP-TIMP interactions. Ann NY Acad Sci 1999, 878:73-91
34. Duffy MJ, McCarthy K: Matrix metalloproteinases in cancer: prognostic markers and targets for therapy (review). Int J Oncol 1998, 12:1343-1348
35. McCarthy K, Maguire T, McGreal G, McDermott E, O'Higgins N, Duffy MJ: High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome In patients with breast cancer. Int J Cancer 1999, 84:44-48
36. Taneja C, Prescott L, Koneru B: Critical preservation injury in rat fatty liver is to hepatocytes, not sinusoidal lining cells. Transplantation 1998, 65:167-172
37. Pankov R, Yamada KM: Fibronectin at a glance. J Cell Sci 2002, 115:3861-3863
38. Wierzbicka-Patynowski I, Schwarzbauer JE: The ins and outs of fibronectin matrix assembly. J Cell Sci 2003, 116:3269-3276
39. Ferguson TA, Mizutani H, Kupper TS: Two integrin-binding peptides abrogate T cell-mediated immune responses in vivo. Proc Natl Acad Sci USA 1991, 88:8072-8076
40. Laffón A, Garcia-Vicuna R, Humbria A, Postigo AA, Corbi AL, de Landazuri MO, Sanchez-Madrid F: Upregulated expression and function of VLA-4 fibronectin receptors on human activated T cells in rheumatoid arthritis. J Clin Invest 1991, 88:546-552
41. Geutskens SB, Nikolic T, Dardenne M, Leenen PJ, Savino W: Defective up-regulation of CD49d in final maturation of NOD mouse macrophages. Eur J Immunol 2004, 34:3465-3476
42. Geutskens SB, Mendes-da-Cruz DA, Dardenne M, Savino W: Fibronectin receptor defects in NOD mouse leucocytes: possible consequences for type 1 diabetes. Scand J Immunol 2004, 60:30-38
43. Jarnagin WR, Rockey DC, Koteliansky VE, Wang SS, Bissell DM: Expression of variant fibronectins in wound healing: cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis. J Cell Biol 1994, 127:2037-2048
44. Werr J, Xie X, Hedqvist P, Ruoslahti E, Lindbom L: β1 integrins are critically involved in neutrophil locomotion in extravascular tissue in vivo. J Exp Med 1998, 187:2091-2096
45. Johnston B, Kubes P: The α4-integrin: an alternative pathway for neutrophil recruitment? Immunol Today 1999, 20:545-550
46. Heit B, Colarusso P, Kubes P: Fundamentally different roles for LFA-1, Mac-1 and α4-integrin in neutrophil chemotaxis. J Cell Sci 2005, 118:5205-5220
47. Kuyvenhoven JP, Ringers J, Verspaget HW, Lamers CB, van Hoek B: Serum matrix metalloproteinase MMP-2 and MMP-9 in the late phase of ischemia and reperfusion injury in human orthotopic liver transplantation. Transplant Proc 2003, 35:2967-2969
48. Kuyvenhoven JP, Verspaget HW, Gao Q, Ringers J, Smit VT, Lamers CB, van Hoek B: Assessment of serum matrix metalloproteinases MMP-2 and MMP-9 after human liver transplantation: increased serum MMP-9 level in acute rejection. Transplantation 2004, 77:1646-1652
49. Leroy V, Monier F, Bottari S, Trocme C, Sturm N, Hilleret MN, Morel F, Zarski JP: Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol 2004, 99:271-279
50. Lohr KM, Kurth CA, Xie DL, Seyer JM, Homandberg GA: The amino-terminal 29- and 72-kd fragments of fibronectin mediate selective monocyte recruitment. Blood 1990, 76:2117-2124
51. Cataldo DD, Tournoy KG, Vermaelen K, Munaut C, Foidart JM, Louis R, Noel A, Pauwels RA: Matrix metalloproteinase-9 deficiency impairs cellular infiltration and bronchial hyperresponsiveness during allergen-induced airway inflammation. Am J Pathol 2002, 161:491-498
52. Kolaczkowska E, Chadzinska M, Scislowska-Czarnecka A, Plytycz B, Opdenakker G, Arnold B: Gelatinase B/matrix metalloproteinase-9 contributes to cellular infiltration in a murine model of zymosan peritonitis. Immunobiology 2006, 211:137-148
53. Belotti D, Paganoni P, Manenti L, Garofalo A, Marchini S, Taraboletti G, Giavazzi R: Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res 2003, 63:5224-5229
54. Annes JP, Munger JS, Rifkin DB: Making sense of latent TGFβ activation. J Cell Sci 2003, 116:217-224
55. Kuyvenhoven JP, Molenaar IQ, Verspaget HW, Veldman MG, Palareti G, Legnani C, Moolenburgh SE, Terpstra OT, Lamers CB, van Hoek B, Porte RJ: Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation: the effect of aprotinin and the relation to ischemia/reperfusion injury. Thromb Haemost 2004, 91:506-513
56. Kornek M, Raskopf E, Guetgemann I, Ocker M, Gerceker S, Gonzalez-Carmona MA, Rabe C, Sauerbruch T, Schmitz V: Combination of systemic thioacetamide (TAA) injections and ethanol feeding accelerates hepatic fibrosis in C3H/He mice and is associated with intrahepatic up regulation of MMP-2, VEGF and ICAM-1. J Hepatol 2006, 45:370-376
57. Gaemers IC, Groen AK: New insights in the pathogenesis of non-alcoholic fatty liver disease. Curr Opin Lipidol 2006, 17:268-273
58. Egeblad M, Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002, 2:161-174
59. Würtz SO, Schrohl AS, Sorensen NM, Lademann U, Christensen IJ, Mouridsen H, Brunner N: Tissue inhibitor of metalloproteinases-1 in breast cancer. Endocr Relat Cancer 2005, 12:215-227